On November, 8, 2026, Allergan Aesthetics announced results from HARMONY IN DIVERSITY and HALO — the first study to evaluate a neurotoxin combined with hyaluronic acid (HA) injectables in adults on glucagon-like peptide-1 (GLP-1) medications in this population.
In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare.
Related: New Survery Shows Gap Between GLP-1 Use and Skin Adaptation
The news is especially relevant for medspa owners and aesthetic practitioners as more patients are seeking solutions for facial volume loss and changes in skin quality, amid GLP-1 medications' surge in the weight-loss landscape.
According to recent data from Guidepoint Qsight, revenue at practices increasingly offering GLP-1 treatments is up by an average of 9%, compared to a 2% decline at practices that did not offer these drugs.
The data were presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego.
"Patients on GLP-1 medications are navigating real changes in how their face looks, and those changes can affect their self-image and how they engage with others," said Joely Kaufman-Janette, M.D., board-certified dermatologist, Skin Research Institute, and study investigator. "Having data specific to this population gives us a clearer starting point for setting expectations and building a treatment plan that reflects what they're experiencing."
Both studies used validated patient questionnaires, including FACE-Q and SKIN-Q. Scores combine answers to multiple questions and range from 0 to 100, with higher scores indicating better outcomes. Mean point improvements reflect the average change in these scores from before treatment.
"Our research is designed around the patients we serve, and that includes people taking GLP-1 medications for weight management," said Darin Messina, Ph.D., senior vice president, head of aesthetics research and development, AbbVie. "Over time, their aesthetic concerns can change and may call for more than one treatment approach. The breadth of the Allergan Aesthetics portfolio lets us study our products in combination to generate evidence that helps providers make informed decisions about their potential use together in practice."
Please see BOTOX® Cosmetic full Prescribing Information, including Boxed Warning and Medication Guide.
